Biogen-backed Estuary nabs $93M for kidney disease gene therapy
BioPharma DiveJacob BellOctober 16, 2026
The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."